Geriatric Nursing
Volume 24, Issue 1 , Pages 56-59 , January 2003

National conference of gerontological nurse practitioners

References 

  1. Kruman I, Kumaravel T, Lohani A, Pedersen R, Cutler Y, Kruman N, et al.  Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002;22:1752–1762
  2. Beck C, Vogelpohl T, Rasin J, Uriri J, O'Sullivan P, Walls R, et al.  Effects of behavioral interventions on disruptive behavior and affect in demented nursing home residents. Nurs Res. 2002;51:219–228
  3. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: The results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry. 2002;63:553–558
  4. Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am. 2002;86:657–674
  5. Doraiswamy PM, Krishnan KR, Anand R, Sohn H, Danyluk J, Hartman RD, et al.  Long-term effects of rivastigmine in moderately severe Alzheimer's disease: Does early initiation of therapy offer sustained benefits?. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:705–712
  6. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev. 2002;(3):CD001747
  7. Potki SG, Anand R, Hartman R, Veach J, Grossberg G. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:713–720
  8. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al.  A multinational randomised 12-week comparative study of donepezil and rivastigmine in patient with mild to moderate Alzheimer's disease. Int J Clin Pract. 2002;127(Suppl):20–36
  9. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, et al.  Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther. 2002;24:862–886
  10. Adams AC. Neurology in primary care. Available at www.fadavis.com2000;
  11. Ballard C, Grace J, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998;351:1032–1033
  12. Campbell S, Stephens S, Ballard C. Dementia with Lewy bodies: Clinical features and treatment. Drugs Aging. 2001;18:397–407
  13. Doubleday EK, Snowden JS, Varma AR, Neary D. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer's disease. J Neurosurg Psychiatr. 2002;72:565–566
  14. Leverenz JB, McKeith IG. Dementia with Lewy bodies. Med Clin North Am. 2002;86:519–535
  15. McKeith IG, Burn D. Spectrum of Parkinson's disease, Parkinson's dementia and Lewy body dementia. Neurol Clin. 2000;18:865–902
  16. McKeith IG, et al.  Guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies. Neurology. 1996;47:1113–1124
  17. National Institute of Neurological Disorders and Stroke. National Institutes of Health. Available at Cited www.ninds.nih.gov/health_and_medical_disorders/dementiawithlewybodies_doc.htm2002 Oct 8;
  18. Pompeu F, Growdon J. Diagnosing dementia with Lewy bodies. Arch Neurol. 2002;59(1):29–30
  19. Santa Cruz K, Walker Z, Swagerty D, et al.  Clinical presentation in monozygotic twins with dementia with Lewy bodies. J Am Med Directors. 2002;3:175–179
  20. Bilikiewicz A, Opala G, Podemski R, Puzynski S, Lapin J, Soltys K, et al.  An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting. Med Sci Monitor. 2002;8(2):PI9–P15
  21. Hageman PA, Thomas VS. Gait performance in dementia: The effects of a 6-week resistance training program in an adult day-care setting. Int J Geriatr Psychiatry. 2002;17:329–334
  22. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310–314
  23. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract. 2002;56:441–446

PII: S0197-4572(02)09001-8

doi: 10.1067/mgn.2003.2

Geriatric Nursing
Volume 24, Issue 1 , Pages 56-59 , January 2003

Article Tools